Yüklüyor......
Hsa-miR-429 promotes bladder cancer cell proliferation via inhibiting CDKN2B
BACKGROUND AND OBJECTIVES: Hsa-miR-429 is increased in bladder cancer. Its roles in bladder cancer are poorly understood. METHODS: The expression levels of hsa-miR-429 and cyclin-dependent kinase inhibitor 2B (CDKN2B) were determined using Real-Time qPCR in a total of 50 patients with bladder cancer...
Kaydedildi:
| Yayımlandı: | Oncotarget |
|---|---|
| Asıl Yazarlar: | , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Impact Journals LLC
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5620291/ https://ncbi.nlm.nih.gov/pubmed/28978151 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19878 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|